Brokerages Set XOMA Royalty Corporation (NASDAQ:XOMA) Price Target at $53.75

XOMA Royalty Corporation (NASDAQ:XOMA) has been given an average rating of “Hold” by the seven brokerages that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $53.75.

Several research firms recently issued reports on XOMA. Lucid Cap Mkts cut XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. HC Wainwright cut XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price objective for the company. in a report on Thursday, April 30th. Benchmark downgraded shares of XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd. Weiss Ratings raised shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 29th. Finally, Zacks Research raised shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 8th.

XOMA Royalty Stock Performance

XOMA opened at $40.17 on Friday. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.96. The stock has a market capitalization of $503.77 million, a PE ratio of 25.59 and a beta of 0.86. The firm has a 50-day moving average price of $41.83 and a two-hundred day moving average price of $34.71. XOMA Royalty has a 1-year low of $22.29 and a 1-year high of $45.22.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.02). The company had revenue of $12.32 million during the quarter, compared to the consensus estimate of $13.91 million. XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%. As a group, equities analysts anticipate that XOMA Royalty will post 0.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On XOMA Royalty

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its position in shares of XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 756 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of XOMA Royalty in the 4th quarter worth $27,000. Tower Research Capital LLC TRC boosted its position in shares of XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,523 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of XOMA Royalty by 266.6% during the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,346 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 543 shares during the period. 95.92% of the stock is owned by institutional investors.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.